CEO: | Lindy Durrant |
CFO: | Sath Nirmalananthan |
Deputy Chairman: | Susan Clement Davies |
Non-Executive Chairman: | Jean-Michel Cosséry |
Non-Executive Dir: | Ursula Ney, Martin Diggle |
Address: | Bellhouse Building, Sanders Road, Oxford Science Park, Oxford, United Kingdom , OX4 4GD |
Website: | http://www.scancell.co.uk/ |
Sector: | Pharma and Biotech(LSE) |
Index: | FTSE AIM All-Share |
ISIN: | GB00B63D3314 |
Currency | UK Pounds |
Share Price | 9.30p |
Change Today | 0.20p |
% Change | 2.20 % |
52 Week High | 17.00 |
52 Week Low | 8.15 |
Volume | 537,268 |
Shares Issued | 927.98m |
Market Cap | £86.30m |
Beta | 0.07 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 2 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
10:13 | 311,978 @ 9.00p |
11:00 | 2,500 @ 8.70p |
11:00 | 2,500 @ 8.70p |
10:25 | 100 @ 9.10p |
09:56 | 11,617 @ 9.01p |
CEO | Lindy Durrant |
CFO | Sath Nirmalananthan |
You are here: research